Image placement plan: one visual may be placed before the main text to highlight the regulatory change affecting children’s care products, microencapsulated fragrance carriers, and export compliance to Europe. On 2026-06-01, the Slovenian Chemicals Office (KUZ) notified a temporary restriction requiring children’s care products containing CMR 1A/1B substances to submit an in vitro release kinetics report for microcapsule encapsulation systems using OECD TG 493, demonstrating that the active ingredient release rate remains below 5% within 48 hours. The measure applies to products such as skin creams, shampoos, and wipes, and extends to fragrance carriers using microencapsulation technology, making it directly relevant to compliance planning for Chinese exporters serving the European market.

Key elements of the temporary restriction

According to the notified measure, all children’s care products containing CMR 1A/1B substances must provide an in vitro release kinetics report for the microcapsule embedding system. The method specified is OECD TG 493. The report must demonstrate that the release rate of active ingredients is below 5% within 48 hours.

The scope described in the event summary covers children’s care products including skin creams, shampoos, and wipes. It also covers fragrance carriers encapsulated by microcapsule technology. Examples of relevant CMR 1A/1B substances mentioned in the summary include certain aldehydes and nitro musks.

The notification was made by the Slovenian Chemicals Office (KUZ) on 2026-06-01 as a temporary restriction. Based on the provided information, the measure directly affects compliance strategies for Chinese exports of microencapsulated fragrances to Europe.

How different market participants may be affected

Export trading companies

These companies may be affected because product access now depends more directly on technical compliance evidence tied to microcapsule release behavior. The impact is likely to appear in export documentation review, customer communication, contract risk checks, and shipment readiness. What deserves closer attention is whether existing product dossiers already contain OECD TG 493-based release kinetics materials and whether product descriptions clearly identify the presence of CMR 1A/1B-related fragrance systems.

Raw material sourcing companies

Companies responsible for sourcing fragrance ingredients, encapsulation materials, or related chemical inputs may be affected because the restriction connects material composition with release performance. The influence may be seen in supplier screening, incoming material evaluation, and specification management. They may need to pay closer attention to whether upstream suppliers can identify relevant CMR 1A/1B substances and support release kinetics assessment for microencapsulated systems.

Processing and manufacturing companies

Manufacturers of children’s care products and microencapsulated fragrance systems may face the most direct operational impact. The affected business stages may include formulation review, encapsulation process control, product testing, technical file preparation, and customer sample approval. From an industry perspective, manufacturers should pay close attention to whether current microcapsule systems can meet the under-5% release threshold within 48 hours and whether existing test reports align with OECD TG 493.

Supply chain service providers

Testing coordinators, compliance consultants, document service providers, and logistics support companies may also be affected. Their role becomes more important where shipments depend on complete technical evidence and accurate document matching. The practical impact may appear in report collection, pre-shipment verification, customs support, and downstream audit response. What deserves closer attention is the timing required to prepare reports and whether document gaps could delay delivery plans.

Practical priorities for companies

Check whether affected products fall within scope

Companies should first identify whether their children’s care products include CMR 1A/1B substances and whether fragrance carriers use microencapsulation technology. This is essential because the requirement is not framed only around finished product type, but also around the presence of relevant substances and the use of encapsulation systems.

Prepare release kinetics evidence under OECD TG 493

The core compliance point in the provided information is the need for an in vitro release kinetics report using OECD TG 493. Companies should focus on whether available testing can demonstrate that active ingredient release remains below 5% within 48 hours. If current technical documentation does not show this clearly, the compliance file may be incomplete for affected products.

Align specifications and technical documents with buyers

Where exports involve European customers, specification alignment may become more detailed for fragrance carriers, especially where microcapsules are used in skin creams, shampoos, or wipes. Companies should review product specifications, technical declarations, and testing attachments to reduce the risk of mismatch between commercial documents and technical evidence.

Review delivery schedules and supplier readiness

Because the requirement adds a specific testing and documentation element, delivery planning may need adjustment. Companies should examine whether suppliers, laboratories, and internal quality teams can support the required report preparation in time. This is particularly relevant for exporters that rely on external fragrance developers or encapsulation technology partners.

Industry observation: compliance is shifting toward performance proof

Analysis shows that this type of measure is better understood not only as a substance-control issue, but also as a performance-verification requirement for encapsulation technology. The key concern is no longer limited to whether a sensitive substance is present; it also concerns how that substance is released from the microcapsule system over time.

From an industry perspective, this may raise the technical threshold for suppliers of microencapsulated fragrances entering regulated applications in children’s care products. Observably, companies with stronger testing coordination, formulation traceability, and technical documentation management may be better positioned to respond. At the same time, it would be inappropriate to treat every impact as immediate market exclusion, because actual implementation details and buyer-side interpretation still need continued observation.

What deserves closer attention is that export compliance strategy may increasingly depend on the ability to connect formulation design, microcapsule engineering, and report-based proof in a consistent file. This could translate into longer preparation cycles and tighter coordination between product development, sourcing, quality, and trade teams.

What this development means for the sector

This temporary restriction is significant because it links children’s product safety control with measurable release behavior in microencapsulated fragrance systems. For companies involved in children’s care products, fragrance carriers, and Europe-bound exports, the immediate relevance lies in documentation readiness and technical verification capability.

A balanced reading is that the measure does not by itself define every future market outcome, but it clearly signals a stricter compliance direction for products involving CMR 1A/1B substances and microcapsule delivery systems. Businesses that respond early through targeted testing, scope review, and document alignment may be better prepared for follow-up regulatory and customer requirements.

Source note and items to watch

This article was generated based on the user-provided news title, event date, and event summary. Typical authoritative source categories for this kind of development may include chemical regulatory authorities, official notifications, testing method references, customs compliance notices, and buyer technical requirement updates. Specific official source links were not provided in the input and should be verified continuously.

Items that still require ongoing observation include the detailed enforcement approach of the temporary restriction, interpretation standards for OECD TG 493 documentation, procurement and specification changes in buyer documents, certification or compliance review practices, and market feedback from affected supply chain participants.